(NASDAQ: UPB) Upstream Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.59%.
Upstream Bio's earnings in 2025 is -$76,395,000.On average, 4 Wall Street analysts forecast UPB's earnings for 2025 to be -$128,738,148, with the lowest UPB earnings forecast at -$146,439,643, and the highest UPB earnings forecast at -$102,454,109. On average, 4 Wall Street analysts forecast UPB's earnings for 2026 to be -$148,987,586, with the lowest UPB earnings forecast at -$174,332,909, and the highest UPB earnings forecast at -$115,864,333.
In 2027, UPB is forecast to generate -$133,925,223 in earnings, with the lowest earnings forecast at -$180,233,407 and the highest earnings forecast at -$72,951,617.